India human papillomavirus (HPV) vaccine market is anticipated
to witness impressive growth during the forecast period. This can be ascribed due to the rise in HPV-related
diseases, such as cervical cancer and other HPV-associated cancers, which have been
increasing in India. This has led to an increased demand for Human
Papillomavirus vaccines to prevent these diseases. Due to the increment in Cervical cancer, it has now
become a significant health burden in India, with an estimated 96,922 new cases
and 60,078 deaths in 2020. The
increasing incidence of cervical cancer is driving demand for human
papillomavirus vaccines as a preventative
measure.
Nowadays, Indian people are
adopting multi-valent
human papillomavirus vaccines, which
protect against several types of HPVs and
offer broader protection against related diseases. The Indian government has also launched
several vaccination programs to increase access to human papillomavirus vaccines,
particularly in rural areas and among disadvantaged populations. These programs
have helped to increase the demand for HPV vaccines in the country. With greater awareness about the health
risks associated with HPV infections, there has been a growing demand for HPV
vaccines among healthcare providers and patients. The availability of HPV vaccines has been increasing in
India, particularly with the introduction of the government's vaccination
programs. This has helped to increase access to HPV vaccines and has
contributed to the growth of the market in India. The India human
papillomavirus vaccine
market was approximately at USD 43.9 Million in 2020 and will probably reach
USD 603.3 Million by 2027, expanding with a compound annual growth rate (CAGR)
of 46.6% during the prophecy period.
Rising Prevalence of Cervical Cancer
In recent years,
there has been a rising prevalence of cervical cancer in India, driven by various
factors, such as low screening rates, limited access to healthcare services,
and low awareness of cervical cancer prevention. Cervical cancer is the
second most common cancer among women in India, accounting for approximately
14% of all female cancers. Nonetheless, the HPV vaccine has the potential
to significantly reduce the incidence of cervical cancer in India, particularly
if it is included in the national immunization program and made widely
available.
The main reason
behind cervical cancer is HPV infection, which is transmitted sexually. The HPV
vaccine is highly effective in preventing HPV infections that cause most cases
of cervical cancer. Several
initiatives have been launched in India to increase awareness about cervical
cancer prevention, including the importance of the human papillomavirus vaccine.
The Indian government has also announced plans to introduce the HPV vaccine
into the national immunization program, which is expected to increase access to
the vaccine and reduce the burden of cervical cancer in the country. the rising
prevalence of cervical cancer in India is a significant driver of the demand
for human papillomavirus vaccines, and efforts to increase access and awareness
about the vaccine are likely to play an important role in reducing the burden
of this disease in the future.
Download Free Sample Report
Improvement In
Healthcare Infrastructure
Improvements in
healthcare infrastructure in India are expected to have a positive impact on
the human papillomavirus vaccine market in
the country, as they can increase access to healthcare services, including
vaccination programs. Over the past few years, the Indian government has made
significant efforts to improve healthcare infrastructure in the country. This
includes initiatives, such as the Ayushman Bharat scheme, which aims to provide
free health insurance coverage to millions of people in India, and the National
Health Mission, which aims to provide universal access to quality healthcare
services across the country. Infrastructural improvement can also lead to
increased awareness about cervical cancer and the importance of HPV vaccination. For example, as more women in
India have access to healthcare services, they may be more likely to receive
cervical cancer screenings and learn about the importance of HPV vaccination as a preventive measure.
The availability of
trained medical professionals also helps the market for the human
papillomavirus vaccine in India to grow. With better healthcare infrastructure,
the availability of trained medical professionals also increases. These medical
professionals can be trained to administer human
papillomavirus vaccines and educate patients about the vaccine and
cervical cancer. Besides, improvements in healthcare infrastructure can also
facilitate the delivery of HPV vaccines,
such as through immunization programs and outreach efforts in rural areas. This
can help to increase the uptake of the vaccine. Improvements in healthcare
infrastructure are expected to be a key driver behind the growth in the India human papillomavirus vaccine market during the
forecast period.
Increasing
Access to Human Papillomavirus Vaccines in India
Improving access
to human papillomavirus (HPV) vaccines is a key focus of the Indian
government's efforts to prevent and control HPV-related diseases. Some of the
initiatives aimed at increasing access to human papillomavirus vaccines in
India include:
The Expanded National Immunization Program: The Government of India has
expanded its National Immunization Program to include the human papillomavirus vaccine.
The vaccine is currently recommended for girls aged 9 to 14 years and is
provided free of cost in government-run healthcare facilities.
Public-Private
Partnerships:
The Government of India has established public-private partnerships to increase
the availability and accessibility of human papillomavirus vaccines. These
partnerships involve collaborations between government agencies, vaccine manufacturers,
and non-governmental organizations (NGOs) to provide vaccines to underserved
populations, such as those in rural areas.
Mobile
Vaccination Units:
To improve access to human papillomavirus vaccines in remote and underserved
areas, the Government of India has launched mobile vaccination units. These
units are equipped with vaccines and trained healthcare providers who visit
schools and other community centers to administer the vaccines.
Awareness and
Education Campaigns:
The government of India has launched awareness and education campaigns to
increase awareness about Human Papillomavirus and the importance of
vaccination. These campaigns target parents, caregivers, and healthcare
providers and aim to dispel myths and misconceptions about Human Papillomavirus
vaccines.
International
Partnerships:
The government of India has formed partnerships with international
organizations, such as the World Health Organization (WHO), to increase access
to Human Papillomavirus vaccines. These partnerships involve the sharing of
knowledge and best practices and the provision of technical assistance and
financial support.
These initiatives
have led to an increase in the availability and accessibility of human
papillomavirus vaccines in India and are expected to contribute to the
reduction of HPV-related diseases in the country and aid the human
papillomavirus vaccine market in the country.
Growing Middle
Class and Disposable Income
As the middle-class
population in India grows, so does disposable income also increase, leading to
greater access to healthcare services, including the Human Papillomavirus
vaccine. With more disposable income, individuals may be more willing and able
to pay for preventative healthcare measures, such as vaccines, that can protect
them against diseases like cervical cancer. Also, the growing middle class in
India is often accompanied by an increase in education and awareness about
health-related issues. As individuals become more aware of the risks associated
with cervical cancer and the benefits of the human papillomavirus vaccine, they
may be more likely to seek out vaccination for themselves and their families.
Besides, the rising middle class can also drive demand for higher quality
healthcare services, which can include access to better and more effective
vaccines, such as human papillomavirus vaccines. the growing middle class and
disposable income in India can help to drive the India human papillomavirus vaccine
market.
Recent
Developments
- In 2021: Hilleman Laboratories, a
joint venture between MSD and Welcome Trust, announced a collaboration with
Indian vaccine manufacturer Bharat Biotech to develop a low-cost Human Papillomavirus vaccine for global
markets.
- In 2019: Serum Institute of
India (SII) entered into a collaboration with MSD to manufacture and sell the two Human Papillomavirus vaccines in low- and middle-income countries. Under the collaboration,
SII will manufacture the vaccine and distribute it in more than 150 countries.
- In 2015: GlaxoSmithKline (GSK) and
MSD announced a joint venture to develop and commercialize a next-generation Human
Papillomavirus vaccine. The vaccine, called V114, received regulatory approval
in India in 2021.
Market
Segmentation
The India human papillomavirus vaccine market can be segmented by valence, disease indication, distribution
channel, and region. By valence
type, the market can be segmented into bivalent,
quadrivalent, nonvalent, and others. By disease indication, the market can be segmented into vaginal cancer, penile cancer, vulvar cancer,
cervical cancer, anal cancer, and others. By distribution channel, the market can be segmented into hospitals & clinics, governmental &
non-governmental organizations, public & private alliances, and others. By Region, the market can be segmented
into North India, South India, East India, and West India.
Market Players
GlaxoSmithKline
Pharmaceuticals Limited, MSD Pharmaceuticals Private Limited, Serum Institute
of India Pvt. Ltd., Bharat Biotech International Limited, HLL Lifecare Limited,
and Panacea Biotec Ltd. are some of the market
players in the India human papillomavirus vaccine market.
|
Attribute
|
Details
|
|
Base
Year
|
2023
|
|
Historic
Data
|
2018 – 2023
|
|
Estimated
Year
|
2024
|
|
Forecast
Period
|
2024 – 2029
|
|
Quantitative
Units
|
Revenue in USD Million, and CAGR for 2018-2023 and 2024-2029
|
|
Report
Coverage
|
Revenue
forecast, company share, competitive landscape, growth factors, and trends
|
|
Segments
Covered
|
Valence
Disease
Indication
Distribution
Channel
Region
|
|
Regional
Scope
|
North
India, South India, East India, West India
|
|
Key
Companies Profiled
|
GlaxoSmithKline Pharmaceuticals Limited, MSD Pharmaceuticals
Private Limited, Serum Institute of India Pvt. Ltd., Bharat Biotech
International Limited, HLL Lifecare Limited, Panacea Biotec Limited.
|
|
Customization
Scope
|
10%
free report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
|
Pricing
and Purchase Options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery
Format
|
PDF and Excel through
Email (We can also provide the editable version of the report in PPT/Word
format on special request)
|
Report Scope:
In this report, the India human papillomavirus vaccine market has been segmented into the following categories, in
addition to the industry trends which have also been detailed below:
·
India Human Papillomavirus Vaccine Market, By Valence:
o Bivalent
o Quadrivalent
o
Nonvalent
·
India Human Papillomavirus Vaccine Market, By Disease Indication:
o Cervical Cancer
o Anal Cancer
o Vaginal Cancer
o Penile Cancer
o
Vulvar Cancer
·
India Human Papillomavirus Vaccine Market, By Distribution Channel:
o Hospitals & Clinics
o Governmental &
Non-Governmental Organizations
o Public & Private Alliances
·
India Human Papillomavirus Vaccine Market, By Region:
o North India
o South India
o East India
o West India
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in the India Human Papillomavirus
Vaccine Market.
Available Customizations:
With the given market data, TechSci
Research offers customizations according to a company’s specific needs. The
following customization options are available for the report:
Company Information
- Detailed analysis and profiling of
additional market players (up to five).
India Human Papillomavirus Vaccine
Market is an upcoming report to be released soon. If you wish an early
delivery of this report or want to confirm the date of release, please contact
us at [email protected]